The FDA selects sponsors for its expedited IND pilot following the October 30, 2026 application deadline.

Question

Six frontier AI models put this at 63% by 14 Nov 2026. Full reasoning from every model.

WillHappen.ai · Accepted Answer

63% — the median of 6 frontier models, resolving by 2026-11-14.

Answer

Gemini (Google): 18% — A 15-day turnaround from application deadline to official pilot selection is far faster than standard FDA administrative cycles. FDA review and interdisciplinary selection panels typically require 30 to 90 days following intake windows to finalize cohorts. Similar CDER/CBER pilots (like Model-Informed Drug Development or CID) historically announced participants months after deadlines. A formal commitment in the Federal Register specifying rapid 14-day rolling selection would dramatically increase these odds.

Answer

Claude (Anthropic): 67% — Hinges on whether FDA sticks to its own stated pilot timeline and announces selections within two weeks of the deadline. FDA set the October 30, 2026 deadline itself and pilots like this typically announce selections promptly to maintain program momentum. A two-week window (Oct 30-Nov 14) is tight, so any administrative delay, review backlog, or government shutdown could push the announcement past Nov 14. Agencies sometimes slip on self-imposed deadlines for new pilot programs, especially involving cross-office coordination on novel application reviews.

Answer

GPT (OpenAI): 58% — FDA must review a just-closed applicant pool and publicly identify selected sponsors within 15 days. The intake closes October 30, leaving FDA only 15 calendar days to screen eligibility and issue selections by November 14. Pilot solicitations often give no firm award date; agencies commonly announce cohorts weeks to months after a deadline. Clear pre-set criteria, a small cohort, or an FDA notice promising rapid notification would materially raise the odds.

Answer

Grok (xAI): 68% — Whether FDA posts accepted-sponsor names within 15 days of the Oct 30 close. FDA must finish completeness checks and internal selection by 14 Nov; two-week windows are rare unless slots are pre-capped and reviews start rolling. Comparable CDER/CBER pilots (START, INTERACT) typically take 4–8 weeks post-deadline to name participants, so this sits below that base rate. A public FAQ or Federal Register notice promising ‘selection by mid-November’ would raise the odds sharply; silence or a ‘review ongoing’ tweet would drop them.

Answer

DeepSeek (DeepSeek): 78% — The FDA must simply announce its internal selections within 15 days, a routine administrative step. Unlike a drug approval, this is an internal FDA administrative selection, which requires no external negotiation or clinical data. The FDA consistently released such pilot participant lists close to 14 days after comparable deadlines (e.g., earlier expedited programs), making a firm post-deadline… The only material risk is a government shutdown or administrative delay pushing the announcement past November 14, but no such disruption is currently indicated.

Answer

Qwen (Alibaba): 38% — Fifteen days post-deadline is tight for FDA to complete review and publicly announce selections. FDA pilot programs typically require 30–90 days post-deadline for review and public announcement of selected participants. A small pilot with narrow criteria could compress the timeline, but internal FDA coordination and clearance processes rarely finish in two weeks. Would move higher if the FDA had pre-committed to a specific announcement date or if the pilot has very few slots with binary eligibility criteria.

The FDA selects sponsors for its expedited IND pilot following the October 30, 2026 application deadline.

An FDA-approved treatment that halts or reverses cognitive decline in Alzheimer's disease becomes available before 2036.

A broad-spectrum curative therapy for metastatic solid tumors is approved before 2035.

An mRNA-based therapeutic cancer vaccine receives full FDA approval for curative intent before 2032.

A definitive cure for at least three of the top five deadliest cancers is approved before 2040.